CAPITAL FUND MANAGEMENT S.A.
Position in RXRX — Recursion Pharmaceuticals, Inc.
CIK 1323645
PARIS, I0
Position in RXRX
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$5,862,103
-$1,413,908 QoQ
Shares Held
1,909,480
+7.3% QoQ
Ownership
0.357%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in RXRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CAPITAL FUND MANAGEMENT S.A. holds $326,278,392 across 42 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
155,904 | $46,931,781 | |
| 2 | INCY |
Incyte Corp
|
336,318 | $38,125,008 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
71,088 | $35,311,542 | |
| 4 | EXEL |
Exelixis, Inc.
|
527,235 | $28,686,856 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
329,554 | $26,130,336 | |
| 6 | MRNA |
Moderna, Inc.
|
277,758 | $19,451,392 | |
| 7 | CORT |
Corcept Therapeutics Inc
|
184,231 | $16,018,885 | |
| 8 | INSM |
INSMED Inc
|
148,976 | $15,883,821 |
All Filings in RXRX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,862,103 | 1,909,480 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $7,276,011 | 1,778,976 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $3,542,997 | 726,024 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $3,645,861 | 720,526 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $1,096,447 | 207,268 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $1,242,460 | 183,796 | Shares | Sole | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||